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ABSTRACT  
In the modern era, chewable tablets are preferred over conventional dosage forms by pediatric, geriatric and bedridden patients due to 
difficulty in swallowing, lesser amount of water for swallowing medications as well as unable to tolerate the bitter taste of  certain drugs. 
Chewable tablets of Desloratadine (DS) were formulated by aqueous and non-aqueous granulation method using water paste and Isopropyl 
alcohol (IPA) as a wetting agents respectively. Desloratadine is used to treat the symptoms of allergy such as sneezing, watery eyes. In the 
recent research, we have formulated eight trials by various concentrations of excipients. For instance; lactose, talcum, magnesium stearate, blue 
color, flavor, aspartame, mannitol, avicel 101 and polyvenylpyrollidine (PVP). Pre-compression and post compression parameters (thickness, 
hardness, friability weight variation and drug content) of the formulations were evaluated. B3 was our optimum dosage form because its 
Hausner’s ratio, compressibility index, bulk density, tap density, angle of repose have optimum values i.e. 1.01, 5.1%, 0.66( g/cc), 0.69(g/cc), 
26.1º respectively and post-compression i.e. thickness, hardness, friability weight variation and drug content have values, 2.9mm, 3.9(kg/cm²), 
0.6%, 99.5% respectively. Tablets prepared by wet granulation technique showed reasonable release profile i.e. 100% within the required time 
i.e. 2 hours.  Moreover, organoleptic evaluation of all formulations were performed. 
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Chewable tablets are the tablets which are required to be 
broken and chewed in between the teeth before ingestion. 
Some children have difficulty in swallowing especially 
pediatric, geriatric and bedridden patients.Selection of 
suitable ingredients during manufacturing a robust solid 
dosage form is required during development of formulations. 
The critical step is the selection of appropriate excipients 
with minimum disintegration time and maximum 
bioavailability during design of solid dosage form. Chewable 
tablets are intended to disintegrate smoothly in mouth at a 
moderate rate either with or without actual chewing. 
Characteristically chewable tablets have a smooth texture 
and pleasant taste upon disintegration1. Antihistamines are 
used as first-line therapy for the treatment of allergic 
rhinitis2. At present, most of signs and symptoms of allergic 
rhinitis are treated by available antihistamines, but they are 
not measured to be very effective for the management of 
congestion3. Therefore, antihistamines are frequently 
administered along with decongestant to reduce nasal 
obstruction. Consumption of antihistamines is minimized 
due to their adverse effects. For instance, use of 
diphenhydramine and chlorpheniramine is condensed as 
compared to new agents i.e. cetirizine and azelastine, 
however, it may causes sedation and psychomotor 
impairment4. Another newer agents i.e. terfenadine and 
astemizole have severe adverse effects e.g. persistence of the 
QTC interval and cardiac arrhythmias5. Uses of several 
antihistamines have also been decreased due to drug and 
food interactions. For example, plasma concentrations of 
terfenadine and astemizole may be increased, when these 
agents are administered concomitantly with cytochrome 
P450 inhibitors such as; erythromycin and ketoconazole5. It 
has been suggested that plasma levels of fexofenadine may 
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be changed due to simultaneous administration of 
erythromycin and ketoconazole, which are drug transporters 
inhibitors or inducer, such as the organic anion transport 
polypeptide (OATP) or P-glycoprotein (P-gp)6. On the other 
side, serum concentration of cetirizine is decreased when the 
product is administered with food5. Desloratadine is a new 
antihistaminic compound, which is active metabolite of 
loratadine. It is approximately 10 to 20 times more potent at 
H1-receptor binding than loratadine in-vitro and 2.5 to 4 
times more antihistaminic potency in animals7.  
Desloratadine was also shown to have a significantly longer 
elimination half-life than loratadine8. 
MATERIALS AND METHODS 
Materials 
Desloratadine (raw material) was gifted by Wimits 
Pharmaceuticals Pvt Ltd.  Lactose, talc, magnesium stearate, 
mannitol were purchased from Sigma-Aldrich (Germany). 
Aspartame, PVP, IPA, Avicel 101 were  purchased from 
Midland Scientific Inc. 
Methods 
Characterization of drug-superdisintegrants 
Fourier transform infrared spectroscopy was used to find the 
physicochemical compatibility between the active 
pharmaceutical ingredient with excepients used in chewable 
tablets9. In this method, spectra of pure drug (Desloratadine) 
and excipients in combination were taken. KBr press (1mg of 
sample in 300mg KBr) was used to prepare transparent 
pallets by applying hydraulic pressure of 8000-20000 psi on 
a pulverized mixture of sample with KBr. Scanning range of 
infrared is 4000-400 cm-1 and the resolution was 2cm-1.  
Compatibility between drug and excipients were evaluated 
by comparing their FTIR spectra with reference spectra of 
pure drug11. 
Micromeritic properties of formulation powder blends 
Powder blends were prepared according to the quantity 
mentioned in Table 1 to analyze the flowability and 
compressibility of desired formulations. Angle of repose, 
bulk density, tapped density, hausner’s ratio, and carr’s index 
was calculated to understand the micromeritic properties of 
powder blends. Angle of repose demonstrates the flow 
properties of the powder blend and was determined by 
funnel method. In this method, Powder blend was filled in 
the funnel and placed 2cm above the smooth surface. 
Accurately weighed powder blend was poured from a funnel 
in such a way that maximum cone height (h) obtained and 
funnel should not exceed more than 1cm above the cone 
height (h)10. Angle of repose was calculated by using the 
following formula. 
Ө = tan-1 (h / r) ...... (Eq1) 
Where “h” is the height and “r” radius of the powder cone. 
Apparent bulk density, tapped density was measured by the 
graduated cylinder method and in g/mL  and hausner ratio 
was calculated by using following formula.  
Hausner ratio =  Tapped density / Bulk density ….. (Eq2) 
The extent of compressibility of powder blends was 
determined by measuring apparent bulk density and tapped 
density and Carr’s index was calculated by following formula. 
C= Tapped density – Bulk density/Tapped density x 100 
Preparation of chewable tablets 
Chewable tablets of desloratadine were prepared by using 
aqueous granulation and non-aqueous granulation method. 
Aqueous Method: 
In this method, active ingredient i.e. desloradine was mixed 
with lactose, avicel 101 and mannitol. Add 10ml of 10% PVP 
and mix, until wet damp mass was formed. Then passed 
damp mass from sieve no.12 and granules were formed. Dry 
these granules in oven at 50˚C for 30 minutes. Then mix it 
with sweetening agent (Mannitol or Aspartame), flavoring 
agent, coloring agent, magnesium stearate and talc. Tablets 
were formed by using single punch machine equipped with 
15mm punch and die11. 
Non-Aqueous Method: 
In this method, active ingredient i.e. desloradine was mixed 
with lactose, avicel 101 and mannitol. Add 10%PVP in 
isopropyl alcohol solution and formed granules. Dried these 
granules in hot air oven at 40-50˚C. Then again pass these 
granules from sieve No. 22. After this, mix it with sweetening 
agent (Mannitol or Aspartame), flavoring agent, coloring 
agent, magnesium stearate and talc. Then this mixture was 
tested for evaluation of the flow properties and made tablets 
by using single punch machine11. 
Composition of formulations is shown in the Table 1. 
 
Table 1: Composition of one tablet of different batches 
Batches Numbers T1 T2 T3 T4 T5 T6 T7 T8 
Chemical Name (mg) (mg) (mg) (mg) (mg) (mg) (mg) (mg) 
1 Desloratadine 5 5 5 5 5 5 5 5 
2 Lactose 164.03 164.03 164.03 164.03 152.03 152.03 152.03 152.03 
3 Aspartame 12 12 _ _ 24 24 _ _ 
4 Mannitol _ _ 12 12 _ _ 24 24 
5 Avicel 101 2 2 2 2 S2 2 2 2 
6 PVP 5.3 5.3 5.3 5.3 5.3 5.3 5.3 5.3 
7 Talc 3.73 3.73 3.73 3.73 3.73 3.73 3.73 3.73 
8 Magnesium 
Stearate 
3.07 3.07 3.07 3.07 3.07 3.07 3.07 3.07 
9 Blue Color 0.23 0.23 0.23 0.23 0.23 0.23 0.23 0.23 
10 Flavor 4.61 4.61 4.61 4.61 4.61 4.61 4.61 4.61 
11 IPA _ 0.12ml _ 0.12ml _ 0.12ml _ 0.12ml 
12 Distilled Water q.s _ q.s _ q.s _ q.s _ 
Each Tablet contains:    Desloratadine USP ……………..  5mg      Batch Size: 200 Tablets 
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Characterization of prepared tablets 
Tablet Hardness 
It is used to determine hardness of the tablets. It is measured 
by selection of randomly three tablets from each formulation 
T1-T8 and placed them horizontally between two arms of 
digital hardness tester (MH-L Galvano Scientific). Breaking 
force is applied until the tablet is broken down. Note the 
value of hardness in kg/cm2. 
Tablet Thickness and Diameter  
It is used to verify thickness and diameter of tablets, place 
the tablet vertically between two arms of the digital 
apparatus (Pharma Test Germany) and note the values that 
appear on the screen of instrument. 
Weight variation  
This test is used to determine individual weight variation of 
tablets from an average weight in order to determine the 
consistency in uniformity of the batch. From each 
formulation 20 tablets were selected randomly and weighed 
on an analytical balance (Shimadzu, Japan). Weight variation 
was calculated according to British Pharmacopeia 
specifications. 
Friability 
Friability of tablets were analyzed by randomly selecting 10 
tablets and placed them in a plastic chamber of Rosch 
Friabilator. The friabilator drum was rotated at 25 rpm for 4 
minutes. The percentage loss in the weight of tablets was 
calculated by the following formula. 
%age Friability = Initial weight – Final weight / initial 
weight x 100 
Drug content determination 
The assay of randomly selected 10 tablets from each batch 
was conducted to determine the content of Desloratadine. 
For this purpose, standard stock solution of pure of 
desloratadine was prepared and then further serial dilutions 
(0.01mg/ml – 0.05mg/ml) were prepared from it. Measure 
the absorbance of the solution at 248nm on UV-visible 
spectrophotometer (PG instruments Ltd) and distilled water 
using as blank. Determine drug content by using given 
equation12. 
% age content = absorbance of sample/absorbance of 
standard x 100 
Percentage drug release 
The dissolution test is used to evaluate the release of a drug 
from its formulation in a desired manner.  To perform 
dissolution test we used Paddle Apparatus. Filled each 
900ml volume with dissolution medium (0.1N HCL) and set 
the temperature 37ºC. Then placed 1 tablet in each beaker 
and took sample after different time intervals (30, 60, 90 and 
120 minutes) and tested under UV spectrophotometer to 
find out the percentage of drug dissolved in medium with 
respect to reference solution i.e. Desloratadine solution13. 
Organoleptic evaluation: 
It is used to determine the taste of the dosage forms by 
means of our senses. It includes the macroscopic appearance 
of the drug, its odor and taste, rarely the sound of its fracture 
and the appearance of the drug to touch. Took 20 healthy 
volunteers, having appropriate sense of taste and ask them 
to chew the tablets and evaluate on the basis of following 
table14. 
Specifications of Organoleptic evaluation are shown in the 
Table 2: 
Table 2: Organoleptic evaluation scale 
Category Scale 




Very Bitter 1 
 
RESULTS  
Characterization of drug-superdisintegrants 
FTIR results of pure drug i.e. Desloratadine and optimum 
dosage form (B3) had shown that all characteristics peaks of 
Desloratadine were appeared in B3. It shows that there were 
no interactions between excipients and desloratadine. Their 
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Micromeritic properties of formulation powder blends 
The bulk and tapped density, compressibility index and Hausner’s ratio of all batches were within the range (less than 1%) as  
shown in the Table 3. 
Table 3: Micromeritics evaluation of powder blend* 




Carr’s Index  
 (%) 





T1 0.76 ± 0.010  0.8 ± 0.013 5 ± 0.894 1.05 ±  0.028 28.5 ± 1.022 Excellent 
T2 0.71 ± 0.012 0.73 ± 0.024 2.7 ± 0.828 1.02 ± 0.016 27.3 ± 0.372 Excellent 
T3  0.66 ± 0.021 0.69 ± 0.058 4.3 ± 0.161 1.04 ± 0.013 26.1 ± 0.920 Excellent 
T4 0.72 ± 0.0360 0.77 ± 0.014 4.2 ± 0.974 1.07 ± 0.097 29 ± 0.635 Excellent 
T5 0.68  ± 0.012 0.79 ± 0.007 4.9 ± 0.501 1.06 ± 0.094 28.9 ± 0.375 Excellent 
T6 0.73 ± 0.047 0.73 ± 0.060 4.8 ± 0.859 1.05 ± 0.011 27.6 ± 0.534 Excellent 
T7 0.74 ± 0.114 0.78 ± 0.152 4.6 ± 0.661 1.03 ± 0.063 28.2 ± 1.045 Excellent 
T8 0.7 ± 0.013 0.75 ± 0.033 4.5 ± 0.706 1.04 ± 0.013 28.1 ± 0.870 Excellent 
 
Characterization of prepared tablets 
All the formulations showed similar thickness. Moreover, friability, hardness, weight variation of all the trials were found to be 
within the official limits as shown in the Table 4. 
Table 4: Characterization of tablets of all formulations 
Sr# Batch No 
Hardness 





1 T1 3.23 0.9 99.6±0.32 2.9±0.2 
2 T2 3.01 0.7 99.8±0.99 2.8±0.2 
3 T3 2.98 0.8 99.7±0.01 2.9±0.2 
4 T4 4.5 0.9 98.9±0.14 2.8±0.2 
5 T5 4.3 0.8 100.2±0.65 2.8±0.2 
6 T6 3.2 0.9 99.6±0.74 2.9±0.2 
7 T7 4.1 0.8 99.8±0.41 2.9±0.2 
8 T8 3.9 0.7 99.9±0.11 2.9±0.2 
 
Percentage content of prepared tablets 
The assay of drug was performed using UV-Spectrophotometer at wavelength 280nm, using 0.1N HCl as blank solution. All the 
formulations were within the specification (95-105%) as per USP. The B3 is considered as more optimized formulation as 
shown in the Table 5. 
Table 5: Percentage content 
Sr# Batch No Percentage purity (%) 
1 T1 97.45 
2 T2 96.1 
3 T3 99.2 
4 T4 95.2 
5 T5 96.3 
6 T6 97.08 
7 T7 97.09 
8 T8 95 
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Percentage drug release 
Percentage cumulative drug release of all 8 formulations of Desloratadine chewable tablets were under the specification as 
shown in the Table 6 and Figure 2. 




Characterization of drug-superdisintegrants 
FTIR spectra of active pharmaceutical ingredient showed the 
main characteristic peaks between 500-1700 cm-1. The 
figure shows also alkene (C=C stretch (conjugated)) at 1610-
1640 cm-1, imines (R2C=N-R stretch) at 1640-1690 cm-1, 
aromatic (C=C stretch) at 1475 cm-1 and 1600 cm-1, (C-H 
stretch) at  3000-3020 cm-1, alkanes (C-H stretch) at 2800-
2950 cm-1 , and amines (N-H bend) 3300-3500 cm-1. 
Characteristic peaks of pure drug appeared in all 
formulations indicates the absence of any interaction with 
the excipients material.  Since there was  no  disappearance 
or change in position of the absorption bands characteristic 
for the drug, which demonstrates the compatibility between 
active ingredient and excepients used during formulation of 
chewable tablets with aqueous and non- aqueous 
techniques. 
Micromeritic properties of formulation powder blends 
The compressibility index for all the formulations was found 
to be within the range 2-5, which indicates the excellent 
properties, the flow properties were further analyzed by 
determining the angle of repose, which were within the 
range of 28 to 30˚. The Hausner’s ratio for all the granules 
formulated are less than 2%, indicating free flow property. 
B3 was our optimum dosage form on the basis of bulk 
density, tapped i.e. 0.71, 0.81 respectively as shown in the 
Table 3.  
Characterization of prepared tablets 
Tablets from different formulations showed hardness in the 
range of 2.98-3.9 Kg/cm2.The friability value is less than 1% 
all formulations were well within the range.  
All batches passed the USP requirement in terms of weight 
variation and drug uniformity as shown in the Table 4. 
Organoleptic evaluation of tablets 
The Studies have shown that taste of formulations have been 
efficiently masked especially the tablets prepared by 










% drug Time(120) % drug 
1 T1 75 85 90 94 
2 T2 78 81 89 95 
3 T3 84 89 91 101 
4 T4 72 79 88 96 
5 T5 80 85 91 93 
6 T6 79 83 91 92 
7 T7 82 88 95 92 
8 T8 81 89 94 90 
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From the recent research, it is concluded through FTIR 
studies that there was no interaction between active 
pharmaceutical ingredient and excipients, so the drug is 
compatible with other excipients. Granules showed excellent 
flow properties and micromeritics parameters of granules 
were found within official limits. The compressibility index 
for all formulations was found to be within the range 2-5. 
The formulated dosage form did not exhibit any sticking, 
capping, edging, lamination and other defects. Post 
compression parameters such as hardness, thickness, 
friability and dissolution time were according to 
specifications. Dissolution rates of chewable tablets prepared 
by aqueous granulation technique were better than tablets 
prepared by non-aqueous techniques. 
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